Exelixis has started the dose-escalation stage of a Phase 1 clinical trial for XB010, targeting patients with locally advanced or metastatic solid tumors

XB010 is an antibody-drug conjugate with a monomethyl auristatin E payload linked to a monoclonal antibody targeting the 5T4 tumor antigen, and was developed through Exelixis’ biotherapeutics collaboration network

The ADC was created using Catalent’s SMARTag site-specific bioconjugation platform, and its 5T4-targeting monoclonal antibody was discovered in partnership with Invenra

The Phase 1 trial will test XB010 both as a single agent and in combination with pembrolizumab to determine its efficacy and tolerability

The trial includes a cohort-expansion stage to further evaluate the drug’s activity and safety in specific cancer indications